$773,879,007
TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN.
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Secure supply of thrombocytopenia treatment for mass casualty events under a 10-year HHS contract that began in 2022.
Ensures U.S. readiness for large-scale disasters or attacks requiring rapid platelet-loss intervention; critical to national emergency response infrastructure.
Locks in Amgen as primary supplier for emergency platelet treatments; signals sustained demand for biologics manufacturing capacity.
Reduces U.S. dependence on foreign sources for critical emergency medical countermeasures; part of broader biodefense supply-chain resilience.
Generated by award_classification v2.1.0 via claude-haiku-4-5-20251001 on 2026-05-17. Cost: $0.003000.
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier CONT_AWD_75A50122C00065_7505_-NONE-_-NONE-.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.